Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Olaparib

First Posted Date: 2014-01-10

Last Posted Date: 2024-08-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 1837

Registration Number: NCT02032823

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Explore the Performance of IntelliCap.

Early Phase 1

Completed

Conditions: Plasma Concentration
Pharmacokinetic Profile

Interventions: Drug: IntelliCap

First Posted Date: 2014-01-01

Last Posted Date: 2016-01-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT02025348

Locations: 🇬🇧
Research Site, Merthyr Tydfil, United Kingdom

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

Phase 1

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: ticagrelor

First Posted Date: 2013-12-30

Last Posted Date: 2018-01-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT02022748

Locations: 🇺🇸
Research Site, Minneapolis, Minnesota, United States

Patient Registry of Roflumilast In Real Life

Completed

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2013-12-19

Last Posted Date: 2017-06-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 1950

Registration Number: NCT02015767

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Phase 1

Completed

Conditions: Healthy Volunteers
Pharmacologic Action

Interventions: Drug: Group 1 AZD3293
Drug: Group 2 AZD3293
Drug: Group 3 AZD3293
Drug: Group 3 Midazolam
Drug: Group 1 Itraconazole
Drug: Group 2 Diltiazem

First Posted Date: 2013-12-13

Last Posted Date: 2014-04-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 56

Registration Number: NCT02010970

Locations: 🇺🇸
Research Site, Cypress, California, United States

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: Epanova
Drug: Olive Oil

First Posted Date: 2013-12-12

Last Posted Date: 2019-09-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 379

Registration Number: NCT02009865

Locations: 🇷🇺
Research Site, Tomsk, Russian Federation

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Phase 1

Completed

Conditions: Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Interventions: Drug: AZD3293
Drug: Placebo

First Posted Date: 2013-12-09

Last Posted Date: 2016-11-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 114

Registration Number: NCT02005211

Locations: 🇯🇵
Research Site, Fukuoka-shi, Japan

REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients

Completed

Conditions: Acute Coronary Syndrome

First Posted Date: 2013-12-05

Last Posted Date: 2014-11-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 814

Registration Number: NCT02001545

Locations: 🇧🇬
Research Site, Vratsa, Bulgaria

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Phase 3

Active, not recruiting

Conditions: Breast Cancer Metastatic
BRCA 1 Gene Mutation
BRCA 2 Gene Mutation

Interventions: Drug: Olaparib
Drug: Physician's choice chemotherapy

First Posted Date: 2013-12-04

Last Posted Date: 2025-04-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 302

Registration Number: NCT02000622

Locations: 🇬🇧
Research Site, Plymouth, United Kingdom

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Phase 3

Completed

Conditions: Acute Ischaemic Stroke
Transient Ischaemic Attack

Interventions: Drug: ticagrelor
Drug: Acetylsalicylic acid (ASA)

First Posted Date: 2013-11-26

Last Posted Date: 2017-06-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 13307

Registration Number: NCT01994720

Locations: 🇻🇳
Research Site, Hochiminh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy